Literature DB >> 25600555

Post-stereotactic radiosurgery brain metastases: a review.

A J Fabiano1, J Qiu.   

Abstract

Stereotactic radiosurgery (SR) is a standard therapy for brain metastases. Radiation necrosis (RN) of the brain is a syndrome of brain coagulative and fibrinoid necrosis and cortical irritation that occurs following radiotherapy. RN following SR peaks in a delayed fashion at 9-12 months postprocedure. Vasogenic cerebral edema secondary to necrosis occurs and can affect surrounding brain function. No definitive non-invasive diagnostic study exists to differentiate post-SR RN from recurrent metastatic tumor. Magnetic resonance (MR) imaging, MR spectroscopy, positron emission tomography, and perfusion-weighted MR imaging have been used to evaluate RN and are discussed. Treatment options for post-SR brain metastases include observation, corticosteroids, pentoxifylline and vitamin E, bevacizumab, radiotherapy, laser-interstitial thermal therapy, and surgical resection.

Entities:  

Mesh:

Year:  2015        PMID: 25600555

Source DB:  PubMed          Journal:  J Neurosurg Sci        ISSN: 0390-5616            Impact factor:   2.279


  3 in total

1.  Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Authors:  Jessica L Narloch; S Harrison Farber; Sarah Sammons; Frances McSherry; James E Herndon; Jenny K Hoang; Fang-Fang Yin; John H Sampson; Peter E Fecci; Kimberly L Blackwell; John P Kirkpatrick; Grace J Kim
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

2.  Bevacizumab for the treatment of post-stereotactic radiosurgery adverse radiation effect.

Authors:  Andrew A Fanous; Andrew J Fabiano
Journal:  Surg Neurol Int       Date:  2016-08-02

3.  Dosimetric Performance and Planning/Delivery Efficiency of a Dual-Layer Stacked and Staggered MLC on Treating Multiple Small Targets: A Planning Study Based on Single-Isocenter Multi-Target Stereotactic Radiosurgery (SRS) to Brain Metastases.

Authors:  Taoran Li; Peyton Irmen; Haisong Liu; Wenyin Shi; Michelle Alonso-Basanta; Wei Zou; Boon-Keng Kevin Teo; James M Metz; Lei Dong
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.